ProfileGDS5678 / 1450718_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 72% 73% 71% 72% 72% 72% 72% 78% 78% 70% 69% 66% 69% 66% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.5276472
GSM967853U87-EV human glioblastoma xenograft - Control 24.6944973
GSM967854U87-EV human glioblastoma xenograft - Control 34.4386471
GSM967855U87-EV human glioblastoma xenograft - Control 44.6563172
GSM967856U87-EV human glioblastoma xenograft - Control 54.5727772
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.5388272
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.5665572
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.3581378
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.4153778
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.3301770
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.237769
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.0027466
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.294269
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.9956566